Overall survival rate estimated at 24 months was 52.4% with generally tolerated safety profile Completed a…
Continue ReadingTag: recurrent

World’s first research centre for recurrent head and neck cancer
The Royal Marsden NHS FT have launched the world’s first research centre for recurrent head and…
Continue Reading